Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy - PubMed
2 hours ago
- #Alzheimer's disease
- #CAR-A therapy
- #amyloid pathology
- Alzheimer's disease (AD) is the leading cause of dementia, characterized by amyloid accumulation and tau-mediated neurodegeneration.
- Current anti-amyloid immunotherapies have limitations, necessitating new therapeutic strategies.
- Researchers introduced anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) and validated their function in vitro.
- Two CAR-A designs were shown to reduce amyloid and associated pathology after plaque formation and prevent early plaque deposition in vivo.
- Single-nucleus RNA sequencing revealed that CAR-A treatment induces a distinct glial response involving coordinated activity of astrocytes and microglia.
- Each CAR-A construct elicits receptor-specific effects in astrocytes or microglia.
- The findings support CAR-A as a potential disease-modifying strategy for AD.